nasal drops raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-14 and is reviewed periodically as new material appears.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
| Property | Value | Notes |
|---|---|---|
| Typical purity | ≥95% by HPLC | Research-grade material |
| Detection wavelength | 214 nm | Peptide bond absorbance |
| Reconstitution medium | Sterile water or saline | Prepare fresh or aliquot immediately |
| Storage (solution) | -80 °C, single-use aliquots | Avoid repeated freeze-thaw cycles |
| Common salt form | Acetate or trifluoroacetate | Affects mass and solubility |
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
As the Kulturkampf declined, debates about the character of the party emerged culminating in the Centre dispute, in 1906, after Julius Bachem had published the article "We must get out of the tower!" He called upon Catholic politicians to fulfill Windthorst's word and get out of their perpetual minority position by an effort to increase Protestant numbers among their representatives in parliament. His proposal was met with passionate opposition by the greater part of Catholic public, especially since it also included the Christian trade unions and other Catholic organisations. No side could win the upper hand, when the outbreak of World War I ended the dispute. After the war, there were many proposals on how the reform the party. Heinrich Brauns published the Cologne Program (Kölner Programm), which proposed the re-formation of the Zentrum under a new name (Christliche Volkspartei, CVP). This proposal was rejected, with only a few regions adopting it for the 1919 election; the party instead adopted the Berlin Guidelines (Berliner Leitsätze), which were more moderate but failed at making the Zentrum attractive for Protestant voters too. Adam Stegerwald, leader of the Christian trade unions, made another attempt at transcending the party's exclusively Catholic character and uniting Germany's fragmented party spectrum. In 1920 he advocated the formation of a broad Christian middle-party, that would transcend denominations and social classes and which could push back the Social Democrats' influence.
== Properties == Flavin adenine dinucleotide consists of two portions: the adenine nucleotide (adenosine monophosphate) and the flavin mononucleotide (FMN) bridged together through their phosphate groups. Adenine is bound to a cyclic ribose at the 1' carbon, while phosphate is bound to the ribose at the 5' carbon to form the adenine nucleotide. Riboflavin is formed by a carbon-nitrogen (C-N) bond between the isoalloxazine and the ribitol. The phosphate group is then bound to the terminal ribose carbon, forming a FMN. Because the bond between the isoalloxazine and the ribitol is not considered to be a glycosidic bond, the flavin mononucleotide is not truly a nucleotide. This makes the dinucleotide name misleading; however, the flavin mononucleotide group is still very close to a nucleotide in its structure and chemical properties.
===== Behavioral treatments ===== A 2018 systematic review and network meta-analysis of 50 trials involving 12 different psychosocial interventions for amphetamine, methamphetamine, or cocaine addiction found that combination therapy with both contingency management and community reinforcement approach had the highest efficacy (i.e., abstinence rate) and acceptability (i.e., lowest dropout rate). Other treatment modalities examined in the analysis included monotherapy with contingency management or community reinforcement approach, cognitive behavioral therapy, 12-step programs, non-contingent reward-based therapies, psychodynamic therapy, and other combination therapies involving these. Additionally, research on the neurobiological effects of physical exercise suggests that daily aerobic exercise, especially endurance exercise (e.g., marathon running), prevents the development of drug addiction and is an effective adjunct therapy (i.e., a supplemental treatment) for amphetamine addiction. Exercise leads to better treatment outcomes when used as an adjunct treatment, particularly for psychostimulant addictions. In particular, aerobic exercise decreases psychostimulant self-administration, reduces the reinstatement (i.e., relapse) of drug-seeking, and induces increased dopamine receptor D2 (DRD2) density in the striatum. This is the opposite of pathological stimulant use, which induces decreased striatal DRD2 density.
non-small cell lung cancers (30–46%) head and neck squamous cell carcinomas (30–50%) pancreatic carcinomas (25%) bladder cancer (15%) pituitary adenomas (49–54%) breast carcinoma (13%) Cyclin D1 overexpression is strongly correlated to ER+ breast cancer and deregulation of cyclin D1 is associated with hormone therapy resistance in breast cancer. Overexpression of Cyclin D1b, an isoform, is also present in breast and prostate cancers. Chromosomal translocation around the cyclin D1 gene locus is often seen in B mantle cell lymphoma. In mantle cell lymphoma, cyclin D1 is translocated to the IgH promoter leading to cyclin D1 overexpression. Chromosomal translocation of the cyclin D1 gene locus is also observed in 15–20% of multiple myelomas.
== Receptor oligomers == Heteromerization with other G protein-coupled receptors (GPCRs) produces complexes with differing ligand selectivity and signaling properties. They show altered G protein coupling, receptor trafficking, and tissue distribution compared to homodimers. Targeting specific KOR-containing heteromers with bivalent ligands may yield analgesics with fewer dysphoric effects, which could be relevant for addiction research and therapy. Heterodimer of KOR with δ-opioid receptor (DOR) is proposed to underlie the pharmacologically defined κ1 subtype and explain region-specific effects like analgesia or dysphoria. Besides KOR-DOR the receptor heterodimerizes with μ-opioid (preferentially forms in females), nociceptin (NOP), orexin receptor 1 (OX1), dopamine transporter (DAT), neurotensin 1, bradykinin B2, beta-2 adrenergic receptors, GPR88. With others possible but not yet definitely established.
Sources: en.wikipedia.org
I am patriot enough to take pains to bring this useful invention into fashion in England, and I should not fail to write to some of our doctors very particularly about it if I knew any one of them that I thought had virtue enough to destroy such a considerable branch of their revenue for the good of mankind, but that distemper is too beneficial to them not to expose to all their resentment the hardy wight that should undertake to put an end to it. Perhaps if I live to return I may, however, have courage to war with them.
=== Influence of temperature, relative humidity and rate of air circulation === The external drying conditions (temperature, relative humidity and air velocity) control the external boundary conditions for drying, and hence the drying rate, as well as affecting the rate of internal moisture movement. The drying rate is affected by external drying conditions, as will now be described.
Electrostatic spray ionization (ESTASI) involved the analysis of samples located on a flat or porous surface, or inside a microchannel. A droplet containing analytes is deposited on a sample area, to which a pulsed high voltage to is applied. When the electrostatic pressure is larger than the surface tension, droplets and ions are sprayed. Secondary electrospray ionization (SESI) is an spray type, ambient ionization method where charging ions are produced by means of an electrospray. These ions then charge vapor molecules in the gas phase when colliding with them. In paper spray ionization, the sample is applied to a piece of paper, solvent is added, and a high voltage is applied to the paper, creating ions.
=== Dietary supplement === In the United States, the extract for use in dietary supplements has self-affirmed generally recognized as safe (GRAS) status, as an ingredient. Supplemental use occurs in various forms, such as root powders, an additive in tea or coffee, and capsules alone or in combination with other ingredients. It is commonly used by bodybuilders or other sports participants in the belief the compound can increase testosterone levels that would improve performance. Available clinical research has found no significant effect of E. longifolia as a supplement. It is under preliminary research for erectile dysfunction, immunomodulation, and other effects. Side effects of using supplements may include nausea, abdominal discomfort, diarrhea, or headaches. Rare cases of liver injury have occurred from its use, mostly in bodybuilders. E. longifolia supplements should not be used during pregnancy. Its long-term safety over regular use has not been adequately assessed.
1962 Waksman Merck postdoc fellowship, USA. 1967 Humboldt assistant professorship stipend at the Max-Planck Institute, Munich, Germany. 1970 visiting professorship at the Weizmann Institute of Science, Rehovot, Israel. 1973 guest professorship in Dallas, Texas, USA. 1978 guest professorship (Japan Society for the Promotion of Science) in Japan. 1982–1986 Full Professor (Ordinarius) in biotechnology at The Federal Institute of technology, ETH Zurich, Switzerland. 1993 honorary visiting professorship in biochemistry at the University of Bath, UK. 1995 honorary visiting professorship in biochemistry at the Université Catholique de Louvain, Louvain-la-Neuve, Belgium. During these stays he collaborated with Nobel Prize winners Lynen, Waksman as well as with Professors Estabrook and Srere, Katchalski-Katzir and Wilchek, Fukui, Chibata, Suzuki, Rees and Creighton respectively.
Sources: en.wikipedia.org
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.
Reversed-phase liquid chromatography establishes purity, while mass spectrometry confirms molecular mass. The two techniques are normally used together. Retention time alone is not sufficient evidence of identity.
Different counterions change the mass per unit of peptide and can shift chromatographic behavior. Two samples of equal stated purity may therefore not be directly comparable. Reports should specify the counterion whenever quantitative comparisons are made.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.